Drugs / CRICTIBANT
CRICTIBANT
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed | US (FDA) | — | angioedema, hereditary, 4 | 2026-07-06 | “FDA) has accepted its New Drug Application (NDA) for deucrictibant immediate-release (IR) capsule (20 mg) for the on-demand treatment (ODT) of Hereditary Angioedema (HAE) attacks.” pharvaris.com ↗ |
| Filed | EU (EMA) | — | angioedema, hereditary, 4 | — | “In July 2026, the European Medicines Agency (EMA) validated the marketing authorization application (MAA) for deucrictibant IR and began its formal review” pharvaris.com ↗ |
Trials 8
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2026-09-08 | Pharvaris Netherlands B.V. | Results Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks pharvaris.com ↗ |
| 2026-09-03 | Pharvaris Netherlands B.V. | Results Pharvaris Presents Translational, Nonclinical, and Clinical Data at Bradykinin Symposium 2026 pharvaris.com ↗
In silico modeling analyses revealed the structural determinants of species-specific differences in deucrictibant binding to the human and rat bradykinin B2 receptor |
| 2026-07-06 | Pharvaris Netherlands B.V. | Regulatory Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks pharvaris.com ↗
today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for deucrictibant immediate-release (IR) capsule (20 mg) for the on-demand treatment (ODT) of Hereditary Angioedema (HAE) attacks. |
| 2026-06-15 | Pharvaris Netherlands B.V. | Results Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026 pharvaris.com ↗
“The data presented at EAACI continue to provide evidence supporting a potentially differentiated profile of deucrictibant in both the on-demand setting and the prophylactic setting,” said Berndt Modig, Chief Executive Officer of Pharvaris. |
| 2026-04-20 | Pharvaris Netherlands B.V. | Results Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference pharvaris.com ↗
The comparable mean total duration of icatibant-treated attacks in the placebo-icatibant and the deucrictibant-icatibant groups provide initial evidence on the efficacy of combining use of a bradykinin B2 receptor antagonist for prophylaxis and on-demand treatment of attacks. |
| 2026-03-20 | Pharvaris Netherlands B.V. | Results Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet Haematology pharvaris.com ↗
RAPIDe-1, a double-blind, placebo-controlled Phase 2 study of deucrictibant immediate-release capsule for the on-demand treatment of HAE attacks, demonstrated a statistically significant reduction in severity of attack manifestations, as well as a reduced time to symptom relief and resolution. |
| 2026-03-02 | Pharvaris Netherlands B.V. | Results Deucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic Treatment of Bradykinin-Mediated Angioedema Presented at AAAAI 2026 pharvaris.com ↗ |
All press releases naming this drug 7 releases
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CRICTIBANT | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095506 ↗ |
| Known as | deucrictibant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05396105 ↗ |
| Known as | PHA-022121 | “Deucrictibant has been adopted as the international nonproprietary name (INN) for the active ingredient, previously referred to as PHA121 or PHA-022121.” NCT07046806 ↗ |
| Known as | PHA121 | “Deucrictibant has been adopted as the international nonproprietary name (INN) for the active ingredient, previously referred to as PHA121 or PHA-022121.” NCT07046806 ↗ |
| Known as | PHVS-719 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095506 ↗ |
| Known as | PHVS416 | “Deucrictibant softgel capsules for oral use (PHVS416)” NCT05047185 ↗ |
| Action | Inhibit | “Deucrictibant is an orally bioavailable bradykinin B2 receptor antagonist” PMID 41865747 ↗ Mar 2026 |
| Modality | Small molecule | — CHEMBL5095506 ↗ |
| Route | Oral | “deucrictibant soft capsules for oral use” NCT04618211 ↗ |